Astria Therapeutics, Inc. (ATXS)
$
12.58
Key metrics
Financial statements
Free cash flow per share
-2.0743
Market cap
718.1 Million
Price to sales ratio
1 Thousand
Debt to equity
0.0191
Current ratio
10.7814
Income quality
0.9654
Average inventory
0
ROE
-0.4501
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Astria Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics aimed at treating rare and niche allergic and immunological diseases in the United States. Its leading product candidate, STAR-0215, is a monoclonal antibody that functions as an inhibitor of plasma kallikrein, currently in the preclinical development phase for hereditary angioedema treatment. The company's operational performance can be assessed through its EBITDA, which stands at -$111,558,000.00 a vital metric reflecting the company's operational profitability. Additionally, the diluted EPS is -$1.68 which accounts for potential share dilution impacts on earnings per share. The EBITDA ratio of 0.00 underscores the company's operational efficiency. As per the latest financial results, Astria recorded an operating income of -$111,558,000.00 showcasing its earnings derived from core operations. Furthermore, the weighted average number of diluted shares outstanding is 56,161,249.00 providing insight into potential dilution effects on existing shareholders. Formerly known as Catabasis Pharmaceuticals, Inc., the company rebranded to Astria Therapeutics, Inc. in September 2021 and has been incorporated since 2008, with its headquarters situated in Boston, Massachusetts. The stock of Astria Therapeutics is currently affordable at $7.05 making it a viable option for budget-conscious investors looking to enter the market. However, it should be noted that the stock experiences a low average trading volume of 1,065,178.00 indicating lower market activity and potentially less liquidity. With a market capitalization of $718,127,262.00 the company is classified as a small-cap player, positioning it within a unique segment of the market. As a key player in the Biotechnology industry, Astria Therapeutics contributes significantly to the overall market landscape by addressing unmet medical needs in its therapeutic areas. Moreover, it belongs to the Healthcare sector, which is characterized by driving innovation and growth in biopharmaceuticals, underscoring its pivotal role in advancing therapeutic options for patients with rare diseases.
What is Astria Therapeutics, Inc. (ATXS)'s stock forecast?
Analysts predict Astria Therapeutics, Inc. stock to fluctuate between $3.56 (low) and $13.29 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Astria Therapeutics, Inc.'s market capitalization?
As of 2026-01-22, Astria Therapeutics, Inc.'s market cap is $718,127,262, based on 57,084,838 outstanding shares.
How does Astria Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Astria Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Astria Therapeutics, Inc. (ATXS) stock?
To buy Astria Therapeutics, Inc. (ATXS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATXS. Place an order (Market, Limit, etc.).
What is the best time to invest in Astria Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Astria Therapeutics, Inc. stock ever split?
Astria Therapeutics, Inc.'s last stock split was 1:6 on 2021-08-20.
How did Astria Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.68 | Growth: -30.58%.
Where can I find Astria Therapeutics, Inc.'s investor relations reports?
Visit https://www.astriatx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Astria Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Astria Therapeutics, Inc. stock?
All-time high: $16.90 (2024-03-25) | All-time low: $2.36 (2022-06-13).
What are the key trends affecting Astria Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
NEW YORK and NEW ORLEANS, Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
globenewswire.com
NEW YORK, Dec. 20, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Astria Therapeutics, Inc.
globenewswire.com
NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Astria Therapeutics, Inc.
globenewswire.com
NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
prnewswire.com
NEW YORK , Oct. 14, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Astria Therapeutics, Inc. (NASDAQ: ATXS ) related to its sale to BioCryst Pharmaceuticals, Inc. Under the terms of the proposed transaction, Astria shareholders will receive $8.55 in cash per share and 0.59 shares of BioCryst common stock per Astria share.
prnewswire.com
MILWAUKEE , Oct. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Astria (NASDAQ: ATXS) for possible breaches of fiduciary duty and other violations of law in its transaction with BioCryst. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
reuters.com
BioCryst Pharmaceuticals said on Tuesday it would buy Astria Therapeutics in a cash-and-stock deal valued at about $700 million, as it looks to expand its portfolio of treatments for rare diseases.
businesswire.com
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present one poster and one oral presentation at the 2025 HAEi Regional Conference EMEA, taking place October 10-12, 2025 in Rome, Italy. Dr. William Lumry, M.D., ARA Research Center, Dallas, TX, United States of America, will share information on the global Phase 3 trial of navenibart in a.
zacks.com
Astria Therapeutics (ATXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
The consensus price target hints at a 294.8% upside potential for Astria Therapeutics (ATXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
See all news
